Revolution Medicines, Inc. (RVMD) 10-Year Financial Performance & Capital Metrics

RVMD •

HealthcareBiotechnologyOncology Therapeutics Developers

AboutRevolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Show more

Revenue $0
EBITDA -$1.17B -72.0%
Net Income -$1.13B -88.5%
EPS (Diluted) -5.95 -66.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -58.07% -98.0%
ROIC -54.33% -61.6%
Debt/Equity 0.10 +62.2%
Interest Coverage -48.80

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 95 (top 5%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 13.3% in last year
✗Expensive at 11.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-88.52%

EPS CAGR

10Y-

5Y-

3Y-

TTM-66.2%

ROCE

10Y Avg-80.65%

5Y Avg-37.82%

3Y Avg-40.51%

Latest-53.04%

Peer Comparison

Oncology Therapeutics Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
EXELExelixis, Inc.	11.81B	44.06	15.85	6.98%	29.63%	31.37%	7.49%	0.08
INCYIncyte Corporation	20.1B	101.27	15.80	21.22%	25.03%	24.9%	6.74%	0.01
GMABGenmab A/S	18.13B	29.44	15.36	30.67%	46.8%	114.25%	6.6%	0.03
SNDXSyndax Pharmaceuticals, Inc.	1.89B	21.71	-5.82		-279.31%	-269.93%		1.20
RCUSArcus Biosciences, Inc.	2.55B	20.37	-6.19	-4.26%	-142.91%	-55.94%		0.16
RLAYRelay Therapeutics, Inc.	1.78B	10.26	-6.37	53.44%	-18.01%	-48.76%		0.06
STROSutro Biopharma, Inc.	1.74B	20.47	-6.92	-59.64%	-205.18%	-234.19%		4.57
OLMAOlema Pharmaceuticals, Inc.	1.66B	24.20	-11			-48.77%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	0	20.16M	50.04M	42.98M	29.39M	35.38M	11.58M	0	0
Revenue Growth %	-	-	148.16%	-14.1%	-31.62%	20.38%	-67.27%	-100%	-
Cost of Goods Sold+	26.59M	0	0	0	0	0	0	0	16.56M
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-26.59M	20.16M	50.04M	42.98M	29.39M	35.38M	11.58M	0	-16.56M
Gross Margin %	-	100%	100%	100%	100%	100%	100%	-	-
Gross Profit Growth %	-	175.85%	148.16%	-14.1%	-31.62%	20.38%	-67.27%	-100%	-
Operating Expenses+	4.54M	60.49M	104.16M	153.68M	217.4M	293.66M	498.76M	689.52M	1.17B
OpEx % of Revenue	-	300%	208.15%	357.54%	739.7%	830.01%	4307.12%	-	-
Selling, General & Admin	4.54M	9.41M	12.41M	21.43M	30.45M	40.59M	75.62M	97.3M	187.13M
SG&A % of Revenue	-	46.66%	24.79%	49.85%	103.61%	114.71%	653.03%	-	-
Research & Development	26.59M	51.08M	91.75M	132.25M	186.95M	253.07M	423.14M	592.23M	978.68M
R&D % of Revenue	-	253.33%	183.36%	307.68%	636.09%	715.3%	3654.09%	-	-
Other Operating Expenses	-26.59M	0	0	0	0	0	0	0	0
Operating Income+	-31.13M	-40.33M	-54.12M	-110.7M	-188.01M	-258.28M	-487.19M	-689.52M	-1.18B
Operating Margin %	-	-199.99%	-108.15%	-257.54%	-639.7%	-730.01%	-4207.12%	-	-
Operating Income Growth %	-	-29.55%	-34.2%	-104.54%	-69.84%	-37.38%	-88.63%	-41.53%	-71.48%
EBITDA+	-29.94M	-38.56M	-50.78M	-104.15M	-180.68M	-248.62M	-477.88M	-677.7M	-1.17B
EBITDA Margin %	-	-191.25%	-101.47%	-242.31%	-614.75%	-702.72%	-4126.74%	-	-
EBITDA Growth %	-	-28.8%	-31.67%	-105.11%	-73.47%	-37.61%	-92.21%	-41.82%	-72.02%
D&A (Non-Cash Add-back)	1.19M	1.76M	3.34M	6.54M	7.33M	9.66M	9.31M	11.82M	16.56M
EBIT	-31.02M	-41.67M	-51.93M	-108.46M	-187.08M	-258.28M	-487.19M	-689.52M	-1.18B
Net Interest Income+	2K	661K	2.08M	2.17M	917K	9.15M	47.18M	86.88M	66.46M
Interest Income	105K	777K	2.19M	2.24M	929K	9.15M	47.48M	86.88M	90.69M
Interest Expense	103K	116K	106K	71K	12K	0	303K	0	24.23M
Other Income/Expense	2K	-1.46M	2.08M	2.17M	917K	9.15M	47.29M	88.68M	51.07M
Pretax Income+	-31.13M	-41.79M	-52.04M	-108.53M	-187.09M	-249.13M	-439.89M	-600.85M	-1.13B
Pretax Margin %	-	-207.24%	-103.99%	-252.5%	-636.58%	-704.14%	-3798.71%	-	-
Income Tax+	105K	0	-4.37M	-371K	0	-420K	-3.52M	-753K	0
Effective Tax Rate %	100%	100%	91.6%	99.66%	100%	99.83%	99.2%	99.87%	100%
Net Income+	-31.13M	-41.79M	-47.66M	-108.16M	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B
Net Margin %	-	-207.24%	-95.25%	-251.63%	-636.58%	-702.95%	-3768.28%	-	-
Net Income Growth %	-	-34.25%	-14.06%	-126.92%	-72.98%	-32.93%	-75.46%	-37.52%	-88.52%
Net Income (Continuing)	-31.13M	-41.79M	-47.66M	-108.16M	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.85	-1.15	-1.31	-1.62	-2.47	-3.08	-3.86	-3.58	-5.95
EPS Growth %	-	-35.29%	-13.91%	-23.66%	-52.47%	-24.7%	-25.32%	7.25%	-66.2%
EPS (Basic)	-0.85	-1.15	-1.31	-1.62	-2.47	-3.08	-3.86	-3.58	-5.95
Diluted Shares Outstanding	36.47M	36.47M	36.47M	66.6M	72.81M	80.63M	113.15M	167.74M	190.13M
Basic Shares Outstanding	36.47M	36.47M	36.47M	66.6M	72.81M	80.63M	113.15M	167.74M	190.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	9.44M	85.43M	133.98M	454.12M	589.77M	660.18M	1.88B	2.33B	2.08B
Cash & Short-Term Investments	9.08M	69.59M	122.76M	440.74M	577.05M	644.94M	1.85B	2.29B	2.03B
Cash Only	9.08M	69.59M	16.66M	104.27M	108.5M	161.41M	696.15M	543.06M	383.75M
Short-Term Investments	0	0	106.1M	336.47M	468.56M	483.53M	1.16B	1.75B	1.64B
Accounts Receivable	0	7.3M	8.74M	6.39M	5.93M	4.67M	1.25M	0	0
Days Sales Outstanding	-	132.19	63.73	54.29	73.63	48.21	39.53	-	-
Inventory	0	6.6M	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	6.6M	0	0	0	10.57M	25.07M	38.33M	49.36M
Total Non-Current Assets+	5.64M	85.16M	86.55M	113.28M	148.22M	151.75M	182.42M	230.67M	279.47M
Property, Plant & Equipment	5.25M	6.87M	7.15M	36.34M	71.24M	73.74M	100.01M	141.82M	165.28M
Fixed Asset Turnover	-	2.93x	7.00x	1.18x	0.41x	0.48x	0.12x	-	-
Goodwill	0	14.61M	14.61M	14.61M	14.61M	14.61M	14.61M	14.61M	14.61M
Intangible Assets	0	63.08M	62.01M	60.95M	59.88M	58.81M	57.74M	56.67M	55.8M
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	383K	593K	2.78M	1.39M	2.5M	4.59M	10.06M	17.57M	43.78M
Total Assets+	15.08M	170.59M	220.53M	567.4M	737.99M	811.93M	2.06B	2.56B	2.35B
Asset Turnover	-	0.12x	0.23x	0.08x	0.04x	0.04x	0.01x	-	-
Asset Growth %	-	1031.43%	29.28%	157.29%	30.06%	10.02%	153.93%	24.09%	-7.97%
Total Current Liabilities+	7.6M	30.55M	43.05M	47.18M	60.35M	61.98M	143.85M	163.91M	290.42M
Accounts Payable	3.35M	5.24M	11.4M	12.61M	14.06M	21.31M	61.79M	54.43M	64.62M
Days Payables Outstanding	46.03	-	-	-	-	-	-	-	1.42K
Short-Term Debt	0	0	0	0	0	0	0	0	16.47M
Deferred Revenue (Current)	0	16.83M	17.12M	12.11M	12.36M	4.46M	0	0	0
Other Current Liabilities	2.55M	6.06M	5.73M	7.83M	10.16M	13.79M	27.51M	31.36M	209.34M
Current Ratio	1.24x	2.80x	3.11x	9.63x	9.77x	10.65x	13.06x	14.20x	7.14x
Quick Ratio	1.24x	2.58x	3.11x	9.63x	9.77x	10.65x	13.06x	14.20x	7.14x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.95M	43.38M	24.94M	45.55M	75.07M	64.76M	91.66M	129.18M	432.79M
Long-Term Debt	0	0	0	0	0	0	0	0	142.23M
Capital Lease Obligations	0	0	0	28.99M	60.42M	57.43M	80.58M	122.97M	0
Deferred Tax Liabilities	0	12.19M	7.82M	7.44M	7.44M	7.03M	3.12M	2.35M	2.35M
Other Non-Current Liabilities	2.95M	2.77M	2.4M	632K	634K	301K	7.97M	3.86M	288.2M
Total Liabilities	10.55M	73.93M	67.99M	92.72M	135.42M	126.74M	235.51M	293.1M	723.21M
Total Debt+	0	147K	0	32.66M	66.63M	64.2M	87.94M	135.84M	158.7M
Net Debt	-9.08M	-69.44M	-16.66M	-71.6M	-41.86M	-97.21M	-608.2M	-407.22M	-225.04M
Debt / Equity	-	0.00x	-	0.07x	0.11x	0.09x	0.05x	0.06x	0.10x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-302.22x	-347.66x	-510.57x	-1559.11x	-15667.33x	-	-1607.87x	-	-48.80x
Total Equity+	4.53M	96.66M	152.53M	474.68M	602.57M	685.19M	1.83B	2.27B	1.63B
Equity Growth %	-	2033.28%	57.81%	211.19%	26.94%	13.71%	166.52%	24.04%	-27.98%
Book Value per Share	0.12	2.65	4.18	7.13	8.28	8.50	16.14	13.50	8.58
Total Shareholders' Equity	4.53M	96.66M	152.53M	474.68M	602.57M	685.19M	1.83B	2.27B	1.63B
Common Stock	0	0	0	7K	8K	9K	16K	18K	19K
Retained Earnings	-67.93M	-109.72M	-157.39M	-265.55M	-452.64M	-701.34M	-1.14B	-1.74B	-2.87B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	74K	116K	-376K	-1.78M	544K	1.32M	3.24M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-25.15M	1.21M	-49.62M	-100.06M	-147.18M	-224.4M	-350.57M	-557.44M	-897.74M
Operating CF Margin %	-	6.02%	-99.15%	-232.8%	-500.78%	-634.26%	-3027.39%	-	-
Operating CF Growth %	-	104.82%	-4190.35%	-101.68%	-47.09%	-52.47%	-56.23%	-59.01%	-61.05%
Net Income	-31.13M	-41.79M	-47.66M	-108.16M	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B
Depreciation & Amortization	1.19M	1.76M	3.34M	6.54M	7.33M	9.66M	9.31M	11.82M	-26.96M
Stock-Based Compensation	141K	855K	3.16M	8.89M	20.72M	31.2M	61.77M	79.2M	118.39M
Deferred Taxes	0	201K	-4.37M	-375K	0	-419K	-3.91M	-762K	0
Other Non-Cash Items	549K	2.12M	373K	1.34M	3.13M	-2.64M	-22.04M	-48.77M	142.13M
Working Capital Changes	4.65M	38.06M	-4.46M	-8.3M	8.72M	-13.49M	40.66M	1.17M	0
Change in Receivables	0	-7.3M	-1.43M	2.34M	464K	1.26M	3.42M	1.25M	0
Change in Inventory	0	0	0	-2.34M	7.68M	0	0	0	0
Change in Payables	1.97M	109K	5.26M	305K	2.24M	7.29M	32.47M	-6.46M	9.54M
Cash from Investing+	-1.57M	-1.34M	-101.97M	-234.23M	-142.12M	-24.12M	-342.6M	-554.39M	118.06M
Capital Expenditures	-1.57M	-1.5M	-2.59M	-2.93M	-6.53M	-10.82M	-7.73M	-10.31M	-15.99M
CapEx % of Revenue	-	7.43%	5.17%	6.82%	22.21%	30.57%	66.74%	-	-
Acquisitions	0	160K	6.2M	231.3M	135.59M	13.3M	0	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-231.3M	-135.59M	-13.3M	0	0	0
Cash from Financing+	22.66M	60.85M	98.66M	422.78M	294.18M	301.43M	1.23B	959.41M	621.52M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-131K	-45K	0	0	0	0	0	8.04M
Other Financing	22.66M	289K	0	2.71M	2.94M	3.39M	836.81M	284K	621.52M
Net Change in Cash	-4.06M	60.72M	-52.93M	88.48M	4.88M	52.91M	534.74M	-153.08M	-158.16M
Free Cash Flow+	-26.72M	-286K	-52.2M	-103M	-153.71M	-235.22M	-358.3M	-567.74M	-913.73M
FCF Margin %	-	-1.42%	-104.32%	-239.62%	-522.99%	-664.83%	-3094.14%	-	-
FCF Growth %	-	98.93%	-18153.5%	-97.29%	-49.24%	-53.03%	-52.33%	-58.45%	-60.94%
FCF per Share	-0.73	-0.01	-1.43	-1.55	-2.11	-2.92	-3.17	-3.38	-4.81
FCF Conversion (FCF/Net Income)	0.81x	-0.03x	1.04x	0.93x	0.79x	0.90x	0.80x	0.93x	0.79x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-686.98%	-82.6%	-38.25%	-34.49%	-34.74%	-38.63%	-34.75%	-29.33%	-58.07%
Return on Invested Capital (ROIC)	-	-266.82%	-49.77%	-30.81%	-29.26%	-33.73%	-40.46%	-33.62%	-54.33%
Gross Margin	-	100%	100%	100%	100%	100%	100%	-	-
Net Margin	-	-207.24%	-95.25%	-251.63%	-636.58%	-702.95%	-3768.28%	-	-
Debt / Equity	-	0.00x	-	0.07x	0.11x	0.09x	0.05x	0.06x	0.10x
Interest Coverage	-302.22x	-347.66x	-510.57x	-1559.11x	-15667.33x	-	-1607.87x	-	-48.80x
FCF Conversion	0.81x	-0.03x	1.04x	0.93x	0.79x	0.90x	0.80x	0.93x	0.79x
Revenue Growth	-	-	148.16%	-14.1%	-31.62%	20.38%	-67.27%	-100%	-

US Stock Screener

...

Revolution Medicines, Inc. (RVMD) 10-Year Financial Performance & Capital Metrics

RVMD •

HealthcareBiotechnologyOncology Therapeutics Developers

Revenue $0
EBITDA -$1.17B -72.0%
Net Income -$1.13B -88.5%
EPS (Diluted) -5.95 -66.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -58.07% -98.0%
ROIC -54.33% -61.6%
Debt/Equity 0.10 +62.2%
Interest Coverage -48.80

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 95 (top 5%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 13.3% in last year
✗Expensive at 11.9x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-88.52%

EPS CAGR

10Y-

5Y-

3Y-

TTM-66.2%

ROCE

10Y Avg-80.65%

5Y Avg-37.82%

3Y Avg-40.51%

Latest-53.04%

Peer Comparison

Oncology Therapeutics Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
EXELExelixis, Inc.	11.81B	44.06	15.85	6.98%	29.63%	31.37%	7.49%	0.08
INCYIncyte Corporation	20.1B	101.27	15.80	21.22%	25.03%	24.9%	6.74%	0.01
GMABGenmab A/S	18.13B	29.44	15.36	30.67%	46.8%	114.25%	6.6%	0.03
SNDXSyndax Pharmaceuticals, Inc.	1.89B	21.71	-5.82		-279.31%	-269.93%		1.20
RCUSArcus Biosciences, Inc.	2.55B	20.37	-6.19	-4.26%	-142.91%	-55.94%		0.16
RLAYRelay Therapeutics, Inc.	1.78B	10.26	-6.37	53.44%	-18.01%	-48.76%		0.06
STROSutro Biopharma, Inc.	1.74B	20.47	-6.92	-59.64%	-205.18%	-234.19%		4.57
OLMAOlema Pharmaceuticals, Inc.	1.66B	24.20	-11			-48.77%		0.00

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	0	20.16M	50.04M	42.98M	29.39M	35.38M	11.58M	0	0
Revenue Growth %	-	-	148.16%	-14.1%	-31.62%	20.38%	-67.27%	-100%	-
Cost of Goods Sold+	26.59M	0	0	0	0	0	0	0	16.56M
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-26.59M	20.16M	50.04M	42.98M	29.39M	35.38M	11.58M	0	-16.56M
Gross Margin %	-	100%	100%	100%	100%	100%	100%	-	-
Gross Profit Growth %	-	175.85%	148.16%	-14.1%	-31.62%	20.38%	-67.27%	-100%	-
Operating Expenses+	4.54M	60.49M	104.16M	153.68M	217.4M	293.66M	498.76M	689.52M	1.17B
OpEx % of Revenue	-	300%	208.15%	357.54%	739.7%	830.01%	4307.12%	-	-
Selling, General & Admin	4.54M	9.41M	12.41M	21.43M	30.45M	40.59M	75.62M	97.3M	187.13M
SG&A % of Revenue	-	46.66%	24.79%	49.85%	103.61%	114.71%	653.03%	-	-
Research & Development	26.59M	51.08M	91.75M	132.25M	186.95M	253.07M	423.14M	592.23M	978.68M
R&D % of Revenue	-	253.33%	183.36%	307.68%	636.09%	715.3%	3654.09%	-	-
Other Operating Expenses	-26.59M	0	0	0	0	0	0	0	0
Operating Income+	-31.13M	-40.33M	-54.12M	-110.7M	-188.01M	-258.28M	-487.19M	-689.52M	-1.18B
Operating Margin %	-	-199.99%	-108.15%	-257.54%	-639.7%	-730.01%	-4207.12%	-	-
Operating Income Growth %	-	-29.55%	-34.2%	-104.54%	-69.84%	-37.38%	-88.63%	-41.53%	-71.48%
EBITDA+	-29.94M	-38.56M	-50.78M	-104.15M	-180.68M	-248.62M	-477.88M	-677.7M	-1.17B
EBITDA Margin %	-	-191.25%	-101.47%	-242.31%	-614.75%	-702.72%	-4126.74%	-	-
EBITDA Growth %	-	-28.8%	-31.67%	-105.11%	-73.47%	-37.61%	-92.21%	-41.82%	-72.02%
D&A (Non-Cash Add-back)	1.19M	1.76M	3.34M	6.54M	7.33M	9.66M	9.31M	11.82M	16.56M
EBIT	-31.02M	-41.67M	-51.93M	-108.46M	-187.08M	-258.28M	-487.19M	-689.52M	-1.18B
Net Interest Income+	2K	661K	2.08M	2.17M	917K	9.15M	47.18M	86.88M	66.46M
Interest Income	105K	777K	2.19M	2.24M	929K	9.15M	47.48M	86.88M	90.69M
Interest Expense	103K	116K	106K	71K	12K	0	303K	0	24.23M
Other Income/Expense	2K	-1.46M	2.08M	2.17M	917K	9.15M	47.29M	88.68M	51.07M
Pretax Income+	-31.13M	-41.79M	-52.04M	-108.53M	-187.09M	-249.13M	-439.89M	-600.85M	-1.13B
Pretax Margin %	-	-207.24%	-103.99%	-252.5%	-636.58%	-704.14%	-3798.71%	-	-
Income Tax+	105K	0	-4.37M	-371K	0	-420K	-3.52M	-753K	0
Effective Tax Rate %	100%	100%	91.6%	99.66%	100%	99.83%	99.2%	99.87%	100%
Net Income+	-31.13M	-41.79M	-47.66M	-108.16M	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B
Net Margin %	-	-207.24%	-95.25%	-251.63%	-636.58%	-702.95%	-3768.28%	-	-
Net Income Growth %	-	-34.25%	-14.06%	-126.92%	-72.98%	-32.93%	-75.46%	-37.52%	-88.52%
Net Income (Continuing)	-31.13M	-41.79M	-47.66M	-108.16M	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.85	-1.15	-1.31	-1.62	-2.47	-3.08	-3.86	-3.58	-5.95
EPS Growth %	-	-35.29%	-13.91%	-23.66%	-52.47%	-24.7%	-25.32%	7.25%	-66.2%
EPS (Basic)	-0.85	-1.15	-1.31	-1.62	-2.47	-3.08	-3.86	-3.58	-5.95
Diluted Shares Outstanding	36.47M	36.47M	36.47M	66.6M	72.81M	80.63M	113.15M	167.74M	190.13M
Basic Shares Outstanding	36.47M	36.47M	36.47M	66.6M	72.81M	80.63M	113.15M	167.74M	190.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	9.44M	85.43M	133.98M	454.12M	589.77M	660.18M	1.88B	2.33B	2.08B
Cash & Short-Term Investments	9.08M	69.59M	122.76M	440.74M	577.05M	644.94M	1.85B	2.29B	2.03B
Cash Only	9.08M	69.59M	16.66M	104.27M	108.5M	161.41M	696.15M	543.06M	383.75M
Short-Term Investments	0	0	106.1M	336.47M	468.56M	483.53M	1.16B	1.75B	1.64B
Accounts Receivable	0	7.3M	8.74M	6.39M	5.93M	4.67M	1.25M	0	0
Days Sales Outstanding	-	132.19	63.73	54.29	73.63	48.21	39.53	-	-
Inventory	0	6.6M	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	6.6M	0	0	0	10.57M	25.07M	38.33M	49.36M
Total Non-Current Assets+	5.64M	85.16M	86.55M	113.28M	148.22M	151.75M	182.42M	230.67M	279.47M
Property, Plant & Equipment	5.25M	6.87M	7.15M	36.34M	71.24M	73.74M	100.01M	141.82M	165.28M
Fixed Asset Turnover	-	2.93x	7.00x	1.18x	0.41x	0.48x	0.12x	-	-
Goodwill	0	14.61M	14.61M	14.61M	14.61M	14.61M	14.61M	14.61M	14.61M
Intangible Assets	0	63.08M	62.01M	60.95M	59.88M	58.81M	57.74M	56.67M	55.8M
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	383K	593K	2.78M	1.39M	2.5M	4.59M	10.06M	17.57M	43.78M
Total Assets+	15.08M	170.59M	220.53M	567.4M	737.99M	811.93M	2.06B	2.56B	2.35B
Asset Turnover	-	0.12x	0.23x	0.08x	0.04x	0.04x	0.01x	-	-
Asset Growth %	-	1031.43%	29.28%	157.29%	30.06%	10.02%	153.93%	24.09%	-7.97%
Total Current Liabilities+	7.6M	30.55M	43.05M	47.18M	60.35M	61.98M	143.85M	163.91M	290.42M
Accounts Payable	3.35M	5.24M	11.4M	12.61M	14.06M	21.31M	61.79M	54.43M	64.62M
Days Payables Outstanding	46.03	-	-	-	-	-	-	-	1.42K
Short-Term Debt	0	0	0	0	0	0	0	0	16.47M
Deferred Revenue (Current)	0	16.83M	17.12M	12.11M	12.36M	4.46M	0	0	0
Other Current Liabilities	2.55M	6.06M	5.73M	7.83M	10.16M	13.79M	27.51M	31.36M	209.34M
Current Ratio	1.24x	2.80x	3.11x	9.63x	9.77x	10.65x	13.06x	14.20x	7.14x
Quick Ratio	1.24x	2.58x	3.11x	9.63x	9.77x	10.65x	13.06x	14.20x	7.14x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.95M	43.38M	24.94M	45.55M	75.07M	64.76M	91.66M	129.18M	432.79M
Long-Term Debt	0	0	0	0	0	0	0	0	142.23M
Capital Lease Obligations	0	0	0	28.99M	60.42M	57.43M	80.58M	122.97M	0
Deferred Tax Liabilities	0	12.19M	7.82M	7.44M	7.44M	7.03M	3.12M	2.35M	2.35M
Other Non-Current Liabilities	2.95M	2.77M	2.4M	632K	634K	301K	7.97M	3.86M	288.2M
Total Liabilities	10.55M	73.93M	67.99M	92.72M	135.42M	126.74M	235.51M	293.1M	723.21M
Total Debt+	0	147K	0	32.66M	66.63M	64.2M	87.94M	135.84M	158.7M
Net Debt	-9.08M	-69.44M	-16.66M	-71.6M	-41.86M	-97.21M	-608.2M	-407.22M	-225.04M
Debt / Equity	-	0.00x	-	0.07x	0.11x	0.09x	0.05x	0.06x	0.10x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-302.22x	-347.66x	-510.57x	-1559.11x	-15667.33x	-	-1607.87x	-	-48.80x
Total Equity+	4.53M	96.66M	152.53M	474.68M	602.57M	685.19M	1.83B	2.27B	1.63B
Equity Growth %	-	2033.28%	57.81%	211.19%	26.94%	13.71%	166.52%	24.04%	-27.98%
Book Value per Share	0.12	2.65	4.18	7.13	8.28	8.50	16.14	13.50	8.58
Total Shareholders' Equity	4.53M	96.66M	152.53M	474.68M	602.57M	685.19M	1.83B	2.27B	1.63B
Common Stock	0	0	0	7K	8K	9K	16K	18K	19K
Retained Earnings	-67.93M	-109.72M	-157.39M	-265.55M	-452.64M	-701.34M	-1.14B	-1.74B	-2.87B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	74K	116K	-376K	-1.78M	544K	1.32M	3.24M
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-25.15M	1.21M	-49.62M	-100.06M	-147.18M	-224.4M	-350.57M	-557.44M	-897.74M
Operating CF Margin %	-	6.02%	-99.15%	-232.8%	-500.78%	-634.26%	-3027.39%	-	-
Operating CF Growth %	-	104.82%	-4190.35%	-101.68%	-47.09%	-52.47%	-56.23%	-59.01%	-61.05%
Net Income	-31.13M	-41.79M	-47.66M	-108.16M	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B
Depreciation & Amortization	1.19M	1.76M	3.34M	6.54M	7.33M	9.66M	9.31M	11.82M	-26.96M
Stock-Based Compensation	141K	855K	3.16M	8.89M	20.72M	31.2M	61.77M	79.2M	118.39M
Deferred Taxes	0	201K	-4.37M	-375K	0	-419K	-3.91M	-762K	0
Other Non-Cash Items	549K	2.12M	373K	1.34M	3.13M	-2.64M	-22.04M	-48.77M	142.13M
Working Capital Changes	4.65M	38.06M	-4.46M	-8.3M	8.72M	-13.49M	40.66M	1.17M	0
Change in Receivables	0	-7.3M	-1.43M	2.34M	464K	1.26M	3.42M	1.25M	0
Change in Inventory	0	0	0	-2.34M	7.68M	0	0	0	0
Change in Payables	1.97M	109K	5.26M	305K	2.24M	7.29M	32.47M	-6.46M	9.54M
Cash from Investing+	-1.57M	-1.34M	-101.97M	-234.23M	-142.12M	-24.12M	-342.6M	-554.39M	118.06M
Capital Expenditures	-1.57M	-1.5M	-2.59M	-2.93M	-6.53M	-10.82M	-7.73M	-10.31M	-15.99M
CapEx % of Revenue	-	7.43%	5.17%	6.82%	22.21%	30.57%	66.74%	-	-
Acquisitions	0	160K	6.2M	231.3M	135.59M	13.3M	0	0	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-231.3M	-135.59M	-13.3M	0	0	0
Cash from Financing+	22.66M	60.85M	98.66M	422.78M	294.18M	301.43M	1.23B	959.41M	621.52M
Debt Issued (Net)	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	0	1000K	1000K	1000K	1000K	1000K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-131K	-45K	0	0	0	0	0	8.04M
Other Financing	22.66M	289K	0	2.71M	2.94M	3.39M	836.81M	284K	621.52M
Net Change in Cash	-4.06M	60.72M	-52.93M	88.48M	4.88M	52.91M	534.74M	-153.08M	-158.16M
Free Cash Flow+	-26.72M	-286K	-52.2M	-103M	-153.71M	-235.22M	-358.3M	-567.74M	-913.73M
FCF Margin %	-	-1.42%	-104.32%	-239.62%	-522.99%	-664.83%	-3094.14%	-	-
FCF Growth %	-	98.93%	-18153.5%	-97.29%	-49.24%	-53.03%	-52.33%	-58.45%	-60.94%
FCF per Share	-0.73	-0.01	-1.43	-1.55	-2.11	-2.92	-3.17	-3.38	-4.81
FCF Conversion (FCF/Net Income)	0.81x	-0.03x	1.04x	0.93x	0.79x	0.90x	0.80x	0.93x	0.79x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-686.98%	-82.6%	-38.25%	-34.49%	-34.74%	-38.63%	-34.75%	-29.33%	-58.07%
Return on Invested Capital (ROIC)	-	-266.82%	-49.77%	-30.81%	-29.26%	-33.73%	-40.46%	-33.62%	-54.33%
Gross Margin	-	100%	100%	100%	100%	100%	100%	-	-
Net Margin	-	-207.24%	-95.25%	-251.63%	-636.58%	-702.95%	-3768.28%	-	-
Debt / Equity	-	0.00x	-	0.07x	0.11x	0.09x	0.05x	0.06x	0.10x
Interest Coverage	-302.22x	-347.66x	-510.57x	-1559.11x	-15667.33x	-	-1607.87x	-	-48.80x
FCF Conversion	0.81x	-0.03x	1.04x	0.93x	0.79x	0.90x	0.80x	0.93x	0.79x
Revenue Growth	-	-	148.16%	-14.1%	-31.62%	20.38%	-67.27%	-100%	-

Revolution Medicines, Inc. (RVMD) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare RVMD vs Peers

vs INCY

vs GMAB

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Revolution Medicines, Inc. (RVMD) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare RVMD vs Peers

vs INCY

vs GMAB

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios